In addition, modulating expression of the p53 family isoforms or targeting their functional pathways linked to MAPK inhibitor resistance could be a potential therapeutic strategy to overcome resistance to MAPK inhibitors in melanoma. This evidence concerns the gene TP53 and melanoma.